Thamer Sliwa

694 total citations
29 papers, 329 citations indexed

About

Thamer Sliwa is a scholar working on Hematology, Genetics and Oncology. According to data from OpenAlex, Thamer Sliwa has authored 29 papers receiving a total of 329 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Hematology, 16 papers in Genetics and 10 papers in Oncology. Recurrent topics in Thamer Sliwa's work include Myeloproliferative Neoplasms: Diagnosis and Treatment (14 papers), Acute Myeloid Leukemia Research (13 papers) and Chronic Myeloid Leukemia Treatments (6 papers). Thamer Sliwa is often cited by papers focused on Myeloproliferative Neoplasms: Diagnosis and Treatment (14 papers), Acute Myeloid Leukemia Research (13 papers) and Chronic Myeloid Leukemia Treatments (6 papers). Thamer Sliwa collaborates with scholars based in Austria, Germany and Switzerland. Thamer Sliwa's co-authors include Sonja Burgstaller, Werner Linkesch, Reinhard Stauder, Richard Greil, Alois Lang, Michael Pfeilstöcker, Martin Schreder, Lisa Pleyer, Michael Girschikofsky and Peter Krippl and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Annals of Oncology.

In The Last Decade

Thamer Sliwa

28 papers receiving 321 citations

Peers

Thamer Sliwa

HEMAT

GENET

ONCOL

GENET

Michael Heinsch Germany

Xiaosha Zhang United States

Eran Zimran Israel

Giuliana Alimena Italy

Irini Xilouri Greece

Rossana Putzulu Italy

Jayashree Motwani United Kingdom

Liwei Fang China

Patrizia Guglielmo Italy

April Sorrell United States

Michael Heinsch Germany

Thamer Sliwa

267 ×1.3

HEMAT

125 ×0.9

GENET

88 ×0.8

48 ×0.6

ONCOL

26 ×0.5

GENET

Citations per year, relative to Thamer Sliwa Thamer Sliwa (= 1×) peers Michael Heinsch

Countries citing papers authored by Thamer Sliwa

Since Specialization

Citations

This map shows the geographic impact of Thamer Sliwa's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thamer Sliwa with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thamer Sliwa more than expected).

Fields of papers citing papers by Thamer Sliwa

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Thamer Sliwa. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thamer Sliwa. The network helps show where Thamer Sliwa may publish in the future.

Co-authorship network of co-authors of Thamer Sliwa

This figure shows the co-authorship network connecting the top 25 collaborators of Thamer Sliwa. A scholar is included among the top collaborators of Thamer Sliwa based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Thamer Sliwa. Thamer Sliwa is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Singer, C, Daniel Egle, Leopold Oehler, et al.. (2025). 356P Real-world (RW) outcomes with first-line (1L) ribociclib (RIB)+endocrine therapy (ET) in patients (pts) with HR+, HER2– metastatic breast cancer (MBC): Final analysis of the phase IV REACH AUT study. ESMO Open. 10. 104927–104927.

Bartsch, Rupert, Gabriel Rinnerthaler, Edgar Petru, et al.. (2023). Updated Austrian treatment algorithm for metastatic triple-negative breast cancer. Wiener klinische Wochenschrift. 136(11-12). 347–361. 1 indexed citations

Bartsch, Rupert, Simon Peter Gampenrieder, Gabriel Rinnerthaler, et al.. (2022). Updated Austrian treatment algorithm in HER2+ metastatic breast cancer. Wiener klinische Wochenschrift. 134(1-2). 63–72. 2 indexed citations

Feenstra, Jelena D. Milosevic, Fiorella Schischlik, Roland Jäger, et al.. (2020). Overexpression of PD-L1 Correlates with JAK2-V617F Mutational Burden and Is Associated with Chromosome 9p Uniparental Disomy in MPN. Blood. 136(Supplement 1). 24–24. 3 indexed citations

Buxhofer‐Ausch, Veronika, Sonja Heibl, Thamer Sliwa, et al.. (2020). Austrian recommendations for the management of essential thrombocythemia. Wiener klinische Wochenschrift. 133(1-2). 52–61. 1 indexed citations

Burgstaller, Sonja, Veronika Buxhofer‐Ausch, Thamer Sliwa, et al.. (2018). Austrian recommendations for the management of polycythemia vera. Wiener klinische Wochenschrift. 130(17-18). 535–542. 3 indexed citations

Krauth, Maria‐Theresa, Sonja Burgstaller, Veronika Buxhofer‐Ausch, et al.. (2018). Ruxolitinib therapy for myelofibrosis in Austria. Wiener klinische Wochenschrift. 130(17-18). 495–504. 5 indexed citations

Aapro, Matti, Ralph V. Boccia, Robert Leonard, et al.. (2017). Refining the role of pegfilgrastim (a long-acting G-CSF) for prevention of chemotherapy-induced febrile neutropenia: consensus guidance recommendations. Supportive Care in Cancer. 25(11). 3295–3304. 53 indexed citations

Aapro, Matti, Ralph V. Boccia, Sylvain Choquet, et al.. (2017). Optimal use of pegfilgrastim (a long-acting granulocyte-colony stimulating factor [G-CSF]) to manage chemotherapy-induced febrile neutropenia (FN) in haematological malignancies: consensus guidance recommendations. European Journal of Cancer. 72. S167–S167. 1 indexed citations

10.

Jeryczynski, Georg, Jürgen Thiele, Bettina Gisslinger, et al.. (2017). Pre‐fibrotic/early primary myelofibrosis vs. WHO‐defined essential thrombocythemia: The impact of minor clinical diagnostic criteria on the outcome of the disease. American Journal of Hematology. 92(9). 885–891. 38 indexed citations

11.

Sperr, Wolfgang R., Susanne Herndlhofer, Karoline V. Gleixner, et al.. (2017). Intensive consolidation with G‐CSF support: Tolerability, safety, reduced hospitalization, and efficacy in acute myeloid leukemia patients ≥60 years. American Journal of Hematology. 92(10). E567–E574. 6 indexed citations

12.

Steger, Guenther G., Edgar Petru, Ferdinand Haslbauer, et al.. (2016). Safety and effectiveness of nab-paclitaxel in young and elderly patients with metastatic breast cancer: a prospective, multicenter non-interventional study. Annals of Oncology. 27. vi74–vi74. 2 indexed citations

13.

Sliwa, Thamer, Christine Beham‐Schmid, Sonja Burgstaller, et al.. (2016). Austrian recommendations for the management of primary myelofibrosis, post-polycythemia vera myelofibrosis and post-essential thrombocythemia myelofibrosis: an expert statement. Wiener klinische Wochenschrift. 129(9-10). 293–302. 6 indexed citations

14.

Pleyer, Lisa, Ulrich Germing, Wolfgang R. Sperr, et al.. (2014). Azacitidine in CMML: Matched-pair analyses of daily-life patients reveal modest effects on clinical course and survival. Leukemia Research. 38(4). 475–483. 44 indexed citations

15.

Gebhart, Johanna, Klaus Lechner, Cathrin Skrabs, et al.. (2014). Lupus anticoagulant and thrombosis in splenic marginal zone lymphoma. Thrombosis Research. 134(5). 980–984. 13 indexed citations

16.

Pleyer, Lisa, Sonja Burgstaller, Michael Girschikofsky, et al.. (2014). Azacitidine in 302 patients with WHO-defined acute myeloid leukemia: results from the Austrian Azacitidine Registry of the AGMT-Study Group. Annals of Hematology. 93(11). 1825–1838. 62 indexed citations

17.

Sliwa, Thamer, et al.. (2013). High spontaneous granulocyte/macrophage-colony formation in patients with myelofibrosis. Leukemia Research. 38(1). 116–120. 1 indexed citations

18.

Nolte, Florian, Emanuele Angelucci, Photis Beris, et al.. (2011). Clinical management of gastrointestinal disturbances in patients with myelodysplastic syndromes receiving iron chelation treatment with deferasirox. Leukemia Research. 35(9). 1131–1135. 12 indexed citations

19.

Pleyer, Lisa, Reinhard Stauder, Sonja Burgstaller, et al.. (2011). Activity of Azacitidine in 26 Unselected, Consecutive CMML Patients Included in the Austrian Azacitidine Registry (AAR) of the AGMT-Study Group. Blood. 118(21). 1715–1715. 1 indexed citations

20.

Sliwa, Thamer & Klaus Geißler. (2008). Leukopenie. 3(3). 161–178. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact